Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Conference call is excellent. These guys sound smart and committed to excellence and success. Happy to be here for years to come.
I will take some profits along the way, including today.
Looking forward to see how much my $1 and .50 calls for 2021 and 2022 go up today. Also have a bunch of $3 calls, also January 2022.
Enjoy the conference call
The last time it broke out around May 18th, it came down exactly like today, then continued gradually upward
There is also 106,000 in open interest in my January, 2022 $1 calls, but oddly, only 7,000 in open interest in my January, 2022 .50 calls.
Been holding those since HEXO was 50 cents. Looking pretty good now.
The morality tale of cannabis sativa: Now is a good time for Filipinos to finally arrive at a sound collective understanding of marijuana as a gift from the plant world
Sylvia L. Mayuga
Published 7:53 PM, November 23, 2019
https://www.rappler.com/move-ph/ispeak/245463-opinion-morality-tale-cannabis-sativa
Thanks, GoSing. Now the move to the NASDAQ makes sense. It's all about the cheese.
https://relivacbd.com/
Reliva cbd
Reliva & ACB = relivacbd.com
Sure. We are only down 86% from our 1 year high of $102.36.
Yeah, those are the real numbers.
And a pearl in my Roth.
Appropriately, the PPS is at $4.20
HEXO Corp., with a market valuation of $178.32 million, currently occupies the Zacks 2 (Buy) slot. The company’s shares have average recommendation of 3.92 compared to the industry’s average recommendation of 1.73. According to Zacks revenue estimates on average, the company is expected to report $52.32 million for current year ended 7/2020. The Zacks Consensus estimates for revenue came out from 7 analysts, whereas the high estimate was $59.71 million and low estimate was $44.43 million.
I agree. It is a relatively small amount to get their foot on the door for CBD sales in the U.S. . 20,000 "distributors" means something. They also have sales from Asia and Europe. Yes, small sales, but that shows an existing infrastructure already in place. ACB will take that infrastructure and run with it.
I think it all comes down to if you believe in the company. And remember, the company is not just the CEO or COO, but also the "best in class" Sky Facilites. There are two in Canada and one in Denmark, although construction has been temporarily halted. ACB is also Radiant Labs, some of the best selling brands across Canada, huge distribution potential with Farmacias in Mexico. And now CBD.
I will continue to add on weakness.
Woodtiger. Welcome to you, a voice of reason.
You have your first follow.
Water Dragon
"That could signal a R/S sometime soon. ACR did it and they shot to the moon, then came crashing back to earth!"
Crashing back to Earth? I bought ACH at 5.80 last week at it is still up 170%.
If that is crashing back to Earth, give me more.
I added $1 2022 HEXO calls yesterday.
Bontooth. I stayed in spirit more than in shares. I have far less now then before. Like many, I got worn down, and then the RS snuffed out my last enthusiasm. Too bad ACB didn't let us in on the good news before the RS and before most everyone sold.
At $16.60 ($1.40 in old shares), we still have a ways to go back up to around $126.00 to retest the all time high.
I do not think it is too late to reenter. I will add a little more whether it goes up or down and then hold.
Marijuana stocks are suddenly back in favor though we all knew that revenues would go back up and costs would go down in 2020. The "turnaround" was no surprise.
But Covid-19 was a surprise. And the markets as a whole are way too high given the depth of recession we are entering, with tens of millions unemployed and infection rates surely to rebound. I believe that we will retest the major indexes lows of March and fail that test, dropping who knows how far.
So, I have one third of my portfolio in bear funds for the QQQ, SPY, Dow and Russel 2000. I don't believe the happy talk.
Reliva CBD Products
Passion for Purity & Purpose in Production
Reliva is a premium CBD products health and wellness company. Our team has years of experience working on behalf of consumers all over the world to help improve their quality of life. With that experience comes hundreds of cycles of product development, feedback, and fine tuning. That is the Reliva CBD product difference, and why Reliva is one of the best selling* retail CBD products companies in the U.S."
You might have gotten some of the splatter, but that egg went on my face.
Thanks for clearing that up, FurtureForSure
As Roseanne Roseannadanna would say, "never mind"
But "a US based Retail Platform with 20,000 plus Retailers" sounds like a pretty good start.
Looks like a good company with wide distribution, domestically, and internationally. The revenue numbers for "the CBD division" will go up dramatically with the synergy of the two companies. IMO, this is a very good deal for ACB
Reliv International Reports First-Quarter Financial Results for 2020
7:00 am ET May 15, 2020 (PR Newswire) Print
Reliv International, Inc. (NASDAQ:RELV), a developer and marketer of nutritional supplements that promote optimal health, today reported its financial results for the first quarter of 2020.
https://mma.prnewswire.com/media/957811/Reliv_International_Logo.jpg
First-Quarter Results
Reliv reported net sales of $10.3 million for the first quarter of 2020 compared with net sales of $9.5 million in the first quarter of 2019. Net sales in the United States increased to $7.8 million in the first quarter of 2019, which represented a 10.3% increase in net sales when compared to the prior-year quarter. Net sales in Reliv's foreign markets increased 2.6% in the first quarter of 2020 compared with the prior-year first quarter. Increases in net sales in Asia and Europe were 10.1% and 2.4%, respectively, in the first quarter of 2020, offset by decreases in net sales in other regions.
Reliv reported net income for the first quarter of 2020 of $662,000 (earnings per diluted share of $0.38) compared to net income of $624,000 (earnings per diluted share of $0.36) in the first quarter of 2019. The income from operations for the first quarter of 2020 was $522,000 compared to $199,000 in the same period in 2019. Results from operations in 2020 were favorably impacted by the improvement in net sales and resulting gross margin in the United States and most of Reliv's foreign markets. Reliv also recognized an income tax benefit of $178,000 in the first quarter of 2020. This benefit was the result of the Coronavirus Aid, Relief, and Economic Security (CARES) Act which was signed into law in late March 2020. Under the CARES Act, the U.S. net operating loss (NOL) arising in our 2018 tax year may be carried back up to five years. Based on this new legislation, we have recognized a $225,000 estimated income tax benefit for the NOL carryback.
Reliv had cash and cash equivalents of $2.8 million as of March 31, 2020, compared to $1.6 million as of December 31, 2019. Net cash provided by operating activities was $1.3 million in the first quarter of 2020.
As of March 31, 2020, Reliv had 13,680 retail customers and Preferred Customers in total - a decrease of 6.9% from March 31, 2019. This count does not include those customers that buy product directly from distributors rather than from us. As of March 31, 2020, Reliv had 25,550 active Distributors - an increase of 1.0% from March 31, 2019. The number of Master Affiliates increased by 7.7% compared to the year-ago total, driven by the growth in Master Affiliates in Asia of 74.3%. Master Affiliate is the level at which Distributors are eligible to earn generation royalties.
"We were pleased with our performance in the first quarter," commented Ryan A. Montgomery, Chief Executive Officer. "It showed the strength of consumer demand for our products, but we recognize a portion of the increase may be due to product supply concerns caused by these uncertain times. We have reassured customers of the continued supply of our products, and in an effort to continue the upward trend in consumer sales, we began offering free enrollments in our Preferred Customer program in April and are continuing this incentive during the month of May."
"To improve our outreach, we have substantially increased our use of online technology as our primary method of communication and training with our customers and distributors as we adapt to the realities of the world today," Montgomery noted. Reliv recently announced that its U.S. distributor conference originally planned to be held in St. Louis in late July will instead be a world-wide online conference. "We felt this was the right decision to make well in advance of the scheduled conference date. We are excited by the opportunity of reaching out to a much larger audience, not only in the United States, but all over the Reliv world."
Prior to the COVID-19 outbreak, Reliv held a successful distributor conference in Dallas in mid-February where the company introduced its latest offering in the RLV line of hemp-extract products--a sleep-aid tincture that includes melatonin.
In international operations, net sales in the Philippines and Europe grew in the first quarter in spite of earlier and more restrictive COVID-19 guidelines than experienced in most of the United States. Net sales in Asia and Europe grew by 10.1% and 2.4%, respectively, in the first quarter of 2020, compared to the prior-year quarter. Montgomery commented, "We are pleased by the resilience of the sales in these regions; however, we are cautious in our plans with the uncertainty of the long-term impact of the pandemic in various parts of the Reliv world."
About Reliv International, Inc.
Reliv International, based in Chesterfield, MO, develops and markets nutritional supplements that promote optimal nutrition. Reliv supplements address core nutrition, targeted solutions and overall wellness and now include a line of RLV hemp extracts. Reliv is the exclusive provider of LunaRich(R) products, which optimize levels of lunasin, a soy peptide that works at the epigenetic level to promote optimal health. The company sells its products through an international network marketing system of independent distributors in 13 countries.
ACB has been the most "popular" pot stock for years. This recent frenzy just confirms that there is still huge interest in the company.
You can figure that this sharp rise was just the "Coming Attractions" for the future of the stock price over the next couple of years.
Right now, it is likely to retrace. I will do as I usually do which is to buy small, but increasing amounts as it goes down, then double down at or near the bottom, and then buy some more as it first starts its climb back up.
That is the plan anyway when emotion doesn't get in the way.
Oh, ok. Lots of claims with new traders on the board.
All I know is I am losing big money on the 2 shares of ACB I still own at 6.50. :)
wEaReLeGiOn, you are a clever guy. I always appreciate your posts
Say what Pinky? I've been on this board and long for 3 years
That's what I thought. Got burned on my few puts I bought on Friday. Sold at open.
So much for my first "straddle."
My .50 and 1.00 calls for 2022 are looking good this morning.
"The story of this board
'I bought in just before the run"
No, really, Buzz, I bought in just before the run at $5.80 and sold at 10.43. :)
And Friday, I bought a few May 22 puts at 9.50, 10.0 amd 11.00
Expecting a pullback tomorrow.
Feeling lucky
And then news like this has got to make you smile.
Cannabis Components To Be Used In Potential COVID-19 Vaccine
Researchers specializing in infectious disease at the University of Saskatchewan in Canada are turning to cannabis as they build a new COVID-19 virus vaccine candidate. The research team says that a plant-based antigen may be easier to produce commercially on a broad scale than animal-based antigens.
Zyus Life Sciences, a medical cannabis company based out of Saskatoon, Saskatchewan, will determine if cannabis-based compounds can play a role in the fight against the novel coronavirus that causes COVID-19. Last year, the company received its license from Health Canada to develop cannabis-based medical products.
https://hightimes.com/health/cannabis-components-used-potential-covid-19-vaccine/
ZYUS Collaborates with USask’s VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19
May. 7, 2020
ZYUS Life Sciences to support research and development of a vaccine for COVID-19
SASKATOON, Saskatchewan--(BUSINESS WIRE)-- ZYUS Life Sciences Inc. ("ZYUS"), a company dedicated to improving quality of life through research and leadership in bio-pharmaceuticals and the development of innovative cannabinoid-based formulations and product candidates, announced today that it is collaborating with the Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) at the University of Saskatchewan, a world leader in developing vaccines and technologies against infectious diseases, to test plant produced antigens in a vaccine for COVID-19.
ZYUS will leverage its bio-pharmaceutical plant technology platform and expertise to develop and express a protein that VIDO-InterVac has identified as a potential antigen for a COVID-19 vaccine. This protein will be isolated by ZYUS in its plant expression system and will provide insights into whether plants can produce antigens that are usable in a COVID-19 vaccine.
“As Canada, and the world, face the challenges of COVID-19, we are proud to partner with VIDO-InterVac to provide Canadian leadership in the development of a vaccine,” said ZYUS CEO, Brent Zettl. “Developing vaccines in plant cells has multiple potential benefits, including the ability to quickly produce a vaccine at scale, having no animal pathogen contaminants, and lower bioreactor processing costs. This is an important initiative for us as an organization, and as citizens looking to make a difference, ZYUS is committing research and development expertise, resources and energy to help find a vaccine now and to develop systems to help respond in the future.”
The approach is one of several that VIDO-InterVac is exploring in an effort to expand vaccine development against this novel coronavirus.
“VIDO-InterVac’s vision is protecting Canada and the world from infectious diseases,” said VIDO-InterVac Director Dr. Volker Gerdts. “Through this partnership, we are exploring alternative methods of antigen production with a goal to potentially expand global vaccine production capacity for COVID-19.”
By mid-summer 2020, ZYUS plans to have extracted enough specific protein through its plant expressions system for VIDO-InterVac to determine its effectiveness in animal models of COVID-19.
About ZYUS Life Sciences Inc.
ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of innovative cannabinoid-based therapeutics and product candidates. Through clinical research and IP development, we intend to deliver high-quality oils, gel-caps, topical creams and other cannabinoid-based therapeutics and product candidates to patients worldwide. The ZYUS vision is to elevate cannabinoids as a standard of care and expand the potential of protein-based formulations in pursuit of a transformational impact on patients’ lives. ZYUS: Advancing the Science of Well-Being. Visit www.zyus.com
https://www.zyus.com/news-and-events/news/news-details/2020/ZYUS-Collaborates-with-USasks-VIDO-InterVac-to-Develop-a-Plant-Based-Vaccine-for-COVID-19/default.aspx
No, I don't regret taking 350% profit when I could have had 475% profit 30 minutes later.
I only remember my big gainers, and big losers, not the what ifs.
ACB has been both a big gainer and a big loser
Yes, my first buy two days ago was a single share at 5.46. Then a bunch more at 5.76, then more 6.00 and then boom.
I've sold 2/3. No more only Buy and Hold for this guy.
I will buy more, hopefully a little lower
I still like the company
TY, and now, I question whether I should have sold this morning, even if for a $300% profit. I did keep my shares, just sold the options.
I always have felt that the underlying company was solid, that the assets and time would Make Aurora Great Again. OMG MAGA
I actually live in a third floor apartment, so the field of hops is even more difficult for me to grow. At most, I can grow enough for two six packs, so I ask myself, is it really worth it?
But, I have had several seasons of balcony grown marijuana with seeds from the Netherlands. With just 3 hours of sun a day, and cool near the ocean, I managed to grow some "stinky" weed. Even from the 3rd floor balcony, the alley below smelled like Bob Marley's front porch. But no one said a word.
I got two grows from one plant the second season. The first yielded about 3 ounces, then the regrow yielded 9 ounces. It was powerful, but I didn't like it all that much. So there I was with 9 ounces. I ended up selling it to my black market dealer and buying half the quantity of bud, that I actually liked at the dispensary.
wEareLeGiOn, I live in a nice suburb here in California. Somehow, my neighbors are upset with me because I am growing a field of hops in my backyard to make my home brew. But mostly, they dislike my 6 eight foot stinky bud marijuana plants that I am legally allowed to grow here.
I plan to make my own personal line of flower (at least 6 strains per quarter) plus oils, shatters, waxes, prerolls, hash, capsules, gelcaps, brownies, bagel bites, vapes, patches, and, of course, both CBD and THC "soft" drinks... Hmmm. Sounds like a lot of work... On second thought, maybe I'll just call one of the 25 delivery dispensaries within 10 minutes of my house and chill.
H ha. TY, Buzz. I just looked at the prices this AM and had to sell my options for a 300% profit.
No mre buy and hold for me. :)
I had to buy some today also. The big O
Looks like my shares bought at $5.73 this morning are doing okay.
I also like the June , 2020 $6.00 call options I got.
Performing on target with revenues is a surprise though it really shouldn't have been.
Maybe I can make back a little of my losses here.
GLTA
Just bought in this morning, Been adding SPXS for a week.
We are going down in the next few months, GLTA
"There's an old saying in Tennessee — I know it's in Texas, probably in Tennessee — that says, fool me once, shame on — shame on you. Fool me — you can't get fooled again."
GWB July 25, 2011
I bought at 5.73, so we shall see. Over-reaction to the downside. Possible earnings surprise coming
I must know something... or nothing. I bought 50 shares of ACB and a few $6 call options for June 19th.
C-P, I believe the long longs are an extinct breed now, like Bigfoot. I haven't seen a long long post a long long message here in a long long time.
You have made your point, perhaps hundreds of times. You have "told us so" hundreds of times.
This long long sold most a couple of months ago, then the rest when I read about the R/S.
I still own a "fun size" MJ portfolio of mostly U.S. MSOs, but my largest holding is SPXS because the markets are irrationally exuberant about a quick economic rebound when we are more likely headed for a depression.
Deaths to Double by August. Stay at Home Orders likely extended through July in California and across the Country. Opened states will be forced to re-close by spikes or local outbreaks. Unemployment will hit 25% or higher by the middle of June. Bankruptcies across multiple industries will accelerate.
If/when all of the Fed stimulus effect has been overwhelmed by the awful reality unfolding, the markets will swoon.
Oh, and I bought a share of ACB today for $5.80, so I am up on my new ACB holdings. Go ACB
"Yes they decided not to proceed with it today cause filthy pelosi wanted all other bs stuff in it"
It always surprises when when an otherwise seemingly sane and intelligent person believes the absolute nonsense and lies told by our Cheeto in Chief and his minions.
For Mr. T and the Repubs the only goal is winning at all costs. Destroy democracy, allow babies in cages, steal as much as possible under the guise of "stimulus" money, but actually funneled to cronies and likely his own bank accounts in Saudi Arabia and Moscow.
But, hey, we agree on CURLF, so whatever. GLTA
This is the most expensive time to buy stocks in 20 years
By Matt Egan, CNN Business
Updated 2:28 PM ET, Tue May 12, 2020
New York (CNN Business)The US stock market stands 4% higher today compared to a year ago, despite the death and destruction unleashed by the coronavirus pandemic.
Although more than 80,000 Americans have died and over 33 million have lost jobs, Wall Street has swiftly recovered from the initial shock delivered by the health crisis. The S&P 500 has spiked 31% since the March 23 lows.
Americans create new economic threat with their own savings
The rapid recovery on Wall Street has lifted market valuations into ultra-rich territory. The S&P 500 now trades at 22.5 times projected earnings, according to Refinitiv, the most expensive valuation since October 2000 during the bursting of the dot-com bubble.
Some experts are warning this euphoria could set the stage for a major setback in the stock market given the steep challenges that still exist.
Even Goldman Sachs, which is bullish on stocks in the long run, is warning clients to brace for a bumpy ride this summer. The investment bank expects the S&P 500 will plunge back to 2,400 over the next three months, representing a potential decline of 18%.
https://www.cnn.com/2020/05/12/investing/stock-market-dow-coronavirus-goldman-sachs/index.html
SPXS